Current guidelines recommend use of dual antiplatelet therapy (DAPT) with aspirin and one of the P2Y12 inhibitors for at least 12-month duration after placing drug-eluting stents (DESs) in patients with acute coronary syndrome (ACS). Acknowledging the fact that bleeding associated with prolonged DAPT therapy can lead to incr eased mortality and morbidity, the authors of T-PASS trial have shown that short-term (< 1 month) use of DAPT followed by use of a potent P2Y12 inhibitor, Ticagrelor, monotherapy for